Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B
Authors:
- 19 May 2016
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 33 (9) , 2098-2106
Abstract
Purpose Fungizone® (AmB-SD), amphotericin B solubilized by sodium deoxycholate, contains a highly aggregated form of the antifungal agent that causes dose-limiting renal toxicity. With the aim of reducing the formulation’s toxicity by co-delivering monomeric amphotericin B (AmB) and sodium supplementation, we deaggregated AmB-SD with FDA-approved excipient PEG-DSPE in 0.9% NaCl-USP. Herein, we describe a reformulated AmB-SD with PEG-DSPE micelles that results in a less toxic drug with maintained antifungal activity. Methods We compared the aggregation state and particle size of AmB-SD alone or combined with PEG-DSPE micelles. In vitro hemolytic activity and in vivo renal toxicity were measured to determine the toxicity of different formulations. In vitro antifungal assays were performed to determine differences in efficacy among formulations. Results PEG-DSPE micelles in saline deaggregated AmB-SD. Deaggregated AmB-SD exhibited significantly reduced in vitro and in vivo toxicity. In vitro antifungal studies showed no difference in minimum inhibitory and fungicidal concentrations of AmB-SD combined with PEG-DSPE relative to the drug alone. Conclusions Reformulation of AmB-SD with PEG-DSPE micelles in saline facilitates co-delivery of monomeric AmB and sodium supplementation, potentially reducing the dose-limiting nephrotoxicity of AmB-SD. Ease of preparation and commercially available components lead us to acknowledge its potential for clinical use.Keywords
Funding Information
- National Institutes of Health (RO1 AI-43346)
This publication has 35 references indexed in Scilit:
- Amphotericin primarily kills yeast by simply binding ergosterolProceedings of the National Academy of Sciences, 2012
- COMMUNICATION: Pharmacokinetics and Nephrotoxicity of Amphotericin B-Incorporated Poly(Ethylene Glycol)-Block-Poly(N-Hexyl Stearate l-aspartamide) MicellesJournal of Pharmaceutical Sciences, 2011
- Amphotericin B Formulations and Drug TargetingJournal of Pharmaceutical Sciences, 2008
- Enzymuria following amphotericin B application in the ratMycoses, 2003
- Amphotericin B Encapsulated in Micelles Based on Poly(ethylene oxide)-block-poly(l-amino acid) Derivatives Exerts Reduced in Vitro Hemolysis but Maintains Potent in Vivo Antifungal ActivityBiomacromolecules, 2003
- Reduced Nephrotoxicity of Conventional Amphotericin B Therapy after Minimal Nephroprotective Measures: Animal Experiments and Clinical StudyThe Journal of Infectious Diseases, 2002
- Mortality and Costs of Acute Renal Failure Associated with Amphotericin B TherapyClinical Infectious Diseases, 2001
- Characterization and Time Dependence of Amphotericin B: Deoxycholate Aggregation by Quasielastic Light ScatteringJournal of Pharmaceutical Sciences, 1991
- Effects of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cellsBiochemical and Biophysical Research Communications, 1988
- Effect of the aggregation state of amphotericin B on its interaction with ergosterolBiochemistry and Cell Biology, 1988